Karglumiinihappo Waymade (Carglumic Acid)

Carglumic acid acts as an analog of N‑acetylglutamate, the natural activator of carbamoyl‑phosphate synthetase I (CPS1). By binding to CPS1, it stimulates the enzyme’s activity, enhancing the conversion of ammonia to carbamoyl phosphate, the first step of the urea cycle, thereby facilitating ammonia detoxification.

The dosage of Karglumiinihappo Waymade is individualized. The prescribing clinician determines the appropriate amount based on the patient’s age, weight, severity of hyperammonemia, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for carglumic acid in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers should discuss the risks and benefits with the patient before initiating therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Carglumic acid is unique in that it directly activates CPS1, whereas other agents such as sodium phenylbutyrate or sodium benzoate act as nitrogen scavengers. This mechanism can provide a more physiological reduction of ammonia, especially in patients with N‑acetylglutamate synthase deficiency, but therapeutic choice depends on individual patient factors.

The product should be stored at room temperature below 25 °C. Keep it in the original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability throughout its shelf life.

Karglumiinihappo Waymade is administered orally. The exact form (tablet, capsule, or liquid) is determined by the manufacturer, and the patient should take it as directed by the prescriber, usually with water and possibly with food to improve tolerability.

Serious risks include hypersensitivity reactions such as rash, angioedema, or anaphylaxis, as well as hepatic dysfunction and metabolic acidosis. Patients should be monitored for signs of liver injury, severe allergic responses, or significant changes in blood pH, and treatment should be stopped if these occur.

Patients with a known hypersensitivity to carglumic acid or any of the product’s excipients should avoid its use. Caution is also advised for individuals with severe hepatic impairment or those taking interacting medications that could exacerbate metabolic disturbances.